Gilead Sciences, Inc. (NASDAQ:GILD) has received an average recommendation of “Buy” from the thirty-three research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation, nineteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $84.40.

A number of equities research analysts have recently issued reports on GILD shares. Berenberg Bank set a $96.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, October 19th. Royal Bank Of Canada began coverage on shares of Gilead Sciences in a report on Thursday, September 14th. They issued an “outperform” rating and a $94.00 price objective for the company. J P Morgan Chase & Co set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Robert W. Baird restated an “outperform” rating and set a $87.00 price objective on shares of Gilead Sciences in a research note on Tuesday, August 29th. Finally, Wells Fargo & Company restated a “market perform” rating and set a $81.00 price objective (up from $73.00) on shares of Gilead Sciences in a research note on Thursday, August 31st.

In other Gilead Sciences news, EVP Gregg H. Alton sold 25,000 shares of Gilead Sciences stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $82.65, for a total transaction of $2,066,250.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 494,999 shares of company stock worth $37,404,139. Company insiders own 1.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of GILD. Welch Investments LLC purchased a new stake in Gilead Sciences in the third quarter worth about $108,000. Penserra Capital Management LLC lifted its stake in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 144 shares during the period. Wealthcare Advisory Partners LLC purchased a new stake in Gilead Sciences in the third quarter worth about $133,000. American Beacon Advisors Inc. purchased a new stake in Gilead Sciences in the first quarter worth about $143,000. Finally, Horan Capital Advisors LLC. purchased a new stake in Gilead Sciences in the third quarter worth about $144,000. 76.23% of the stock is owned by institutional investors.

Gilead Sciences (NASDAQ GILD) traded down $0.59 during trading on Thursday, reaching $72.70. 1,927,618 shares of the company were exchanged, compared to its average volume of 9,215,772. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The company has a market cap of $95,736.46, a price-to-earnings ratio of 7.65, a PEG ratio of -1.23 and a beta of 1.13. Gilead Sciences has a twelve month low of $63.76 and a twelve month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the prior year, the firm posted $2.75 EPS. Gilead Sciences’s revenue was down 13.2% on a year-over-year basis. research analysts anticipate that Gilead Sciences will post 8.53 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.86%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s payout ratio is currently 23.69%.

WARNING: “Gilead Sciences, Inc. (GILD) Receives Consensus Rating of “Buy” from Analysts” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/07/gilead-sciences-inc-gild-receives-consensus-rating-of-buy-from-analysts.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.